<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36259277</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>09</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2328-9503</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>11</Issue><PubDate><Year>2022</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Annals of clinical and translational neurology</Title><ISOAbbreviation>Ann Clin Transl Neurol</ISOAbbreviation></Journal><ArticleTitle>Impact of the National Amyotrophic Lateral Sclerosis Registry: Analysis of Registry-funded Research.</ArticleTitle><Pagination><StartPage>1692</StartPage><EndPage>1701</EndPage><MedlinePgn>1692-1701</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/acn3.51660</ELocationID><Abstract><AbstractText Label="OBJECTIVE">This research aims to examine the impact of the National Amyotrophic Lateral Sclerosis (ALS) Registry-funded research activities.</AbstractText><AbstractText Label="METHODS">Registry-funded research and related publications were identified through the National ALS Registry website, the National Institutes of Health (NIH) Reporter website, and verified by Principal Investigators. Key study characteristics (e.g., study population, sample size) and key impact features (e.g., risk factors) were abstracted and recorded on study abstraction forms. Descriptive statistics were used to analyze the volume, productivity, and findings of the Registry-funded research.</AbstractText><AbstractText Label="RESULTS">Since 2012, the National ALS Registry funded 21 research projects. Of these, 14 were through extramural research grants and included in the analysis. These studies are often related to environmental, medical conditions, and genetic risk factors. On average, the funded grants produced 1 to 2 publications which were cited 114 times by other researchers. The relative citation ratio averaged 1.81 with a weighted relative citation ratio of 16.28. These studies supported the identification and confirmation of candidate risk factors. Environmental and occupational risk factors typically related to heavy metal exposure (e.g., lead, mercury) and agricultural chemicals (e.g., pesticides, herbicides), and the occupations associated with exposure to these substances were most frequently explored.</AbstractText><AbstractText Label="INTERPRETATION">The National ALS Registry is a multifaceted research platform, one component of which is funded research. This Registry-funded research fills an essential gap in the overall ALS scientific community as it is difficult to prevent and treat a disease without a deeper understanding of its causes.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rechtman</LastName><ForeName>Lindsay</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-8629-3881</Identifier><AffiliationInfo><Affiliation>McKing Consulting Corporation, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brenner</LastName><ForeName>Stephan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centers for Disease Control and Prevention/Agency for Toxic Substances and Disease Registry, National ALS Registry (CDC/ATSDR), Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wright</LastName><ForeName>Marcienne</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centers for Disease Control and Prevention/Agency for Toxic Substances and Disease Registry, National ALS Registry (CDC/ATSDR), Atlanta, Georgia, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>U.S. Public Health Service Commissioned Corps, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ritsick</LastName><ForeName>Maggie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>McKing Consulting Corporation, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rahman</LastName><ForeName>Farhana</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Centers for Disease Control and Prevention/Agency for Toxic Substances and Disease Registry, National ALS Registry (CDC/ATSDR), Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Moon</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centers for Disease Control and Prevention/Agency for Toxic Substances and Disease Registry, National ALS Registry (CDC/ATSDR), Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raymond</LastName><ForeName>Jaime</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Centers for Disease Control and Prevention/Agency for Toxic Substances and Disease Registry, National ALS Registry (CDC/ATSDR), Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Larson</LastName><ForeName>Theodore</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Centers for Disease Control and Prevention/Agency for Toxic Substances and Disease Registry, National ALS Registry (CDC/ATSDR), Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horton</LastName><ForeName>D Kevin</ForeName><Initials>DK</Initials><AffiliationInfo><Affiliation>Centers for Disease Control and Prevention/Agency for Toxic Substances and Disease Registry, National ALS Registry (CDC/ATSDR), Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mehta</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Centers for Disease Control and Prevention/Agency for Toxic Substances and Disease Registry, National ALS Registry (CDC/ATSDR), Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Clin Transl Neurol</MedlineTA><NlmUniqueID>101623278</NlmUniqueID><ISSNLinking>2328-9503</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010575">Pesticides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019216">Metals, Heavy</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010575" MajorTopicYN="Y">Pesticides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019216" MajorTopicYN="Y">Metals, Heavy</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declared that they have no conflict of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>19</Day><Hour>4</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36259277</ArticleId><ArticleId IdType="pmc">PMC9639630</ArticleId><ArticleId IdType="doi">10.1002/acn3.51660</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mehta P, Raymond J, Punjani R, et&#xa0;al. Prevalence of amyotrophic lateral sclerosis in the United States using established and novel methodologies, 2017. Amyotroph Lateral Scler Frontotemporal Degener. 2022;1&#x2010;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9568617</ArticleId><ArticleId IdType="pubmed">35422180</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P, Raymond J, Punjani R, et&#xa0;al. Incidence of amyotrophic lateral sclerosis in the United States, 2014&#x2013;2016. Amyotroph Lateral Scler Frontotemporal Degener. 2022;23:1&#x2010;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">35023792</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards D, Morren JA, Pioro EP. Time to diagnosis and factors affecting diagnostic delay in amyotrophic lateral sclerosis. J Neurol Sci. 2020;417:117054.</Citation><ArticleIdList><ArticleId IdType="pubmed">32763509</ArticleId></ArticleIdList></Reference><Reference><Citation>Kj&#xe6;ldgaard A&#x2010;L, Pilely K, Olsen KS, et&#xa0;al. Prediction of survival in amyotrophic lateral sclerosis: a nationwide, Danish cohort study. BMC Neurol. 2021;21(1):164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8052712</ArticleId><ArticleId IdType="pubmed">33865343</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsumoto H, Chad DA, Pioro EP. Amyotrophic Lateral Sclerosis. Contemporary Neurology Series. Oxford University Press and A F. A. Davis Co.; 1998.</Citation></Reference><Reference><Citation>Pugh KH, Zarus GM. The burden of environmental disease in the United States. J Environ Health. 2012;74(9):30&#x2010;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">22590849</ArticleId></ArticleIdList></Reference><Reference><Citation>ALS Registry Act. 110th Congress; 2008.</Citation></Reference><Reference><Citation>Raymond J, Oskarsson B&#xd6;, Mehta P, Horton K. Clinical characteristics of a large cohort of US participants enrolled in the National Amyotrophic Lateral Sclerosis (ALS) Registry, 2010&#x2013;2015. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(5&#x2013;6):413&#x2010;420.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6946020</ArticleId><ArticleId IdType="pubmed">31131638</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P, Raymond J, Han MK, et&#xa0;al. Recruitment of patients with amyotrophic lateral sclerosis for clinical trials and epidemiological studies: descriptive study of the national ALS Registry's research notification mechanism. J Med Internet Res. 2021;23(12):e28021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8693186</ArticleId><ArticleId IdType="pubmed">34878988</ArticleId></ArticleIdList></Reference><Reference><Citation>Bledsoe MJ, Rechtman L, Wagner L, Mehta P, Horton DK, Kaye WE. Analysis of biospecimen demand and utilization of samples from the National Amyotrophic Lateral Sclerosis Biorepository. Biopreserv Biobanking. 2021;19(5):432&#x2010;437.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9082877</ArticleId><ArticleId IdType="pubmed">34264761</ArticleId></ArticleIdList></Reference><Reference><Citation>
ATSDR
. 
Substance Priority List
. Accessed June 26, 2022. https://www.atsdr.cdc.gov/spl/
</Citation></Reference><Reference><Citation>Raymond J, Mehta P, Larson T, Pioro EP, Horton DK. Reproductive history and age of onset for women diagnosed with amyotrophic lateral sclerosis: data from the national ALS registry: 2010&#x2013;2018. Neuroepidemiology. 2021;55(5):416&#x2010;424.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8506649</ArticleId><ArticleId IdType="pubmed">34218222</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrew A, Zhou J, Gui J, et&#xa0;al. Pesticides applied to crops and amyotrophic lateral sclerosis risk in the U.S. Neurotoxicology. 2021;87:128&#x2010;135.</Citation><ArticleIdList><ArticleId IdType="pubmed">34562505</ArticleId></ArticleIdList></Reference><Reference><Citation>
ATSDR
. 
Toxicological Profiles
. Accessed June 26, 2022. https://www.atsdr.cdc.gov/toxprofiledocs/index.html
</Citation></Reference><Reference><Citation>
ATSDR
. 
Place and Health
. Accessed June 26, 2022. https://www.atsdr.cdc.gov/placeandhealth/index.html
</Citation></Reference><Reference><Citation>
ATSDR
. 
Division of Toxicology and Human Health Sciences (DTHHS)
. Accessed June 26, 2022. https://www.atsdr.cdc.gov/dthhs/office_of_director/comp_tox_lab.html
</Citation></Reference><Reference><Citation>
CDC
. 
Genomics &amp; Precision Health
. Accessed June 26, 2022. https://www.cdc.gov/genomics/default.htm
</Citation></Reference><Reference><Citation>Ryan M, Vaillant TZ, RL ML, et&#xa0;al. Comparison of the clinical and genetic features of amyotrophic lateral sclerosis across Cuban, Uruguayan and Irish clinic&#x2010;based populations. J Neurol Neurosurg Psychiatry. 2019;90(6):659.</Citation><ArticleIdList><ArticleId IdType="pubmed">30846540</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsumoto H, Garofalo DC, Gilmore M, et&#xa0;al. Case&#x2010;control study in ALS using the national ALS registry: lead and agricultural chemicals are potential risk factors. Amyotroph Lateral Scler Frontotemporal Degener. 2022;23(3&#x2013;4):190&#x2010;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">34137650</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrew AS, Caller TA, Tandan R, et&#xa0;al. Environmental and occupational exposures and amyotrophic lateral sclerosis in New England. Neurodegener Dis. 2017;17(2&#x2013;3):110&#x2010;116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5383428</ArticleId><ArticleId IdType="pubmed">28122372</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuczmarski T, Stommel EW, Riley K, et&#xa0;al. Medical history of chemotherapy or immunosuppressive drug treatment and risk of amyotrophic lateral sclerosis (ALS). J Neurol. 2017;264(8):1763&#x2010;1767.</Citation><ArticleIdList><ArticleId IdType="pubmed">28711998</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrew AS, Chen CY, Caller TA, et&#xa0;al. Toenail mercury levels are associated with amyotrophic lateral sclerosis risk. Muscle Nerve. 2018;58(1):36&#x2010;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6034986</ArticleId><ArticleId IdType="pubmed">29314106</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrew AS, Pioro EP, Li M, et&#xa0;al. The incidence of amyotrophic lateral sclerosis in Ohio 2016&#x2013;2018: the Ohio population&#x2010;based ALS registry. Neuroepidemiology. 2021;55(3):196&#x2010;205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8220927</ArticleId><ArticleId IdType="pubmed">33902051</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrew AS, O&#x2019;Brien KM, Jackson BP, et&#xa0;al. Keratinous biomarker of mercury exposure associated with amyotrophic lateral sclerosis risk in a nationwide U.S. study. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21(5&#x2013;6):420&#x2010;427.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7483924</ArticleId><ArticleId IdType="pubmed">32329357</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrew AS, Bradley WG, Peipert D, et&#xa0;al. Risk factors for amyotrophic lateral sclerosis: a regional United States case&#x2010;control study. Muscle Nerve. 2021;63(1):52&#x2010;59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7821307</ArticleId><ArticleId IdType="pubmed">33006184</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman SA et&#xa0;al. Untargeted metabolomics yields insight into ALS disease mechanisms. J Neurol Neurosurg Psychiatry. 2020;91(12):1329.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7677469</ArticleId><ArticleId IdType="pubmed">32928939</ArticleId></ArticleIdList></Reference><Reference><Citation>De Marchi F, Munitic I, Amedei A, et&#xa0;al. Interplay between immunity and amyotrophic lateral sclerosis: clinical impact. Neurosci Biobehav Rev. 2021;127:958&#x2010;978.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8428677</ArticleId><ArticleId IdType="pubmed">34153344</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdock BJ, Famie JP, Piecuch CE, et&#xa0;al. NK cells associate with ALS in a sex&#x2010; and age&#x2010;dependent manner. JCI Insight. 2021;6(11):1&#x2010;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8262328</ArticleId><ArticleId IdType="pubmed">33974561</ArticleId></ArticleIdList></Reference><Reference><Citation>Figueroa&#x2010;Romero C, Monteagudo A, Murdock BJ, et&#xa0;al. Tofacitinib suppresses natural killer cells in&#xa0;vitro and in&#xa0;vivo: implications for amyotrophic lateral sclerosis. Front Immunol. 2022;13:1&#x2010;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8859451</ArticleId><ArticleId IdType="pubmed">35197969</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman SA, Guo K, Savelieff MG, et&#xa0;al. Metabolomics identifies shared lipid pathways in independent amyotrophic lateral sclerosis cohorts. Brain. 2022; 1&#x2010;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">35088843</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>